Streetbeat News

Price Targets

BNTX

Over the past 3 months, 5 Wall Street analysts have published their ratings on BioNTech (NASDAQ:BNTX), with 2 bullish and 3 indifferent ratings. The average 12-month price target for BNTX is $129.0, with a high of $180.00 and a low of $110.00. This average has decreased by 2.64% from the previous target of $132.50. Analysts typically review stocks quarterly or after major company updates, basing their predictions on financial forecasts and company performance.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:00 pm

ON

ON Semiconductor (NASDAQ:ON) received 15 analyst ratings in the last quarter, with an average 12-month price target of $88.2, a decrease of 25.01% from the previous target of $117.62. The ratings include 5 bullish, 3 somewhat bullish, and 7 indifferent, with no bearish or somewhat bearish ratings. Analysts' opinions can provide guidance but are subjective and part of broader financial analysis.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:00 pm

KMDA

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Kamada (NASDAQ:KMDA) and maintained the price target of $11.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:00 pm

CURI

Needham analyst Laura Martin has reiterated a Buy rating on CuriosityStream (NASDAQ:CURI) and maintained a price target of $1.5.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:52 am

PLX

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Protalix BioTherapeutics (AMEX:PLX) and maintained a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:50 am

CLSD

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a price target of $6. The reaffirmation of the Buy rating and price target suggests a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:48 am

ARTL

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Artelo Biosciences (NASDAQ:ARTL) and maintained a $5 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:46 am

SENS

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Senseonics Holdings (AMEX:SENS) with a maintained price target of $2.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:45 am

EYEN

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Eyenovia (NASDAQ:EYEN) and maintained a $12 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:41 am

SPRO

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a $7 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:31 am